NCT05093335 - In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Non-Hodgkin LymphomaMultiple MyelomaHistiocytic NeoplasmsErdheim-Chester DiseaseRosai-Dorfman Disease

Interventions

DRUG

[68Ga]-Pentixafor

An intravenous bolus of 3 -5 mCi of \[68Ga\]-Pentixafor will be injected in all participants.

Trial Locations (1)

RECRUITING

Memorial Sloan Kettering Cancer Center, New York